SELLAS Life Sciences Group (SLS) EBIT: 2011-2023
Historic EBIT for SELLAS Life Sciences Group (SLS) over the last 4 years, with Dec 2023 value amounting to -$8.2 million.
- SELLAS Life Sciences Group's EBIT rose 13.43% to -$8.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$37.9 million, marking a year-over-year increase of 9.73%. This contributed to the annual value of -$37.9 million for FY2023, which is 9.73% up from last year.
- According to the latest figures from Q4 2023, SELLAS Life Sciences Group's EBIT is -$8.2 million, which was up 12.65% from -$9.4 million recorded in Q3 2023.
- Over the past 5 years, SELLAS Life Sciences Group's EBIT peaked at -$2.2 million during Q1 2021, and registered a low of -$16.7 million during Q1 2022.
- For the 3-year period, SELLAS Life Sciences Group's EBIT averaged around -$8.8 million, with its median value being -$8.8 million (2022).
- As far as peak fluctuations go, SELLAS Life Sciences Group's EBIT soared by 44.76% in 2021, and later crashed by 645.43% in 2022.
- SELLAS Life Sciences Group's EBIT (Quarterly) stood at -$4.2 million in 2020, then slumped by 179.37% to -$11.6 million in 2021, then rose by 18.70% to -$9.4 million in 2022, then grew by 13.43% to -$8.2 million in 2023.
- Its EBIT stands at -$8.2 million for Q4 2023, versus -$9.4 million for Q3 2023 and -$9.1 million for Q2 2023.